Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2022

View Archived Issues

Discovery of GB-1101, selective oral HDAC6 inhibitor with potent antitumor activity in vivo

Gannex Pharma presents new FXR agonists

Novel biomarkers for identifying progression of diabetic retinopathy

XuanZhu Pharma divulges AhR antagonists

Gasherbrum Bio identifies new GLP-1 receptor agonists

New PADI4 inhibitors disclosed by Helios-Huaming BioPharma

Jiangsu Simcere Pharmaceutical synthesizes new Mat2A inhibitors

Celgene ERK/NLK inhibitor CC-91516 shows activity against BRAF and CTNNB1 mutant tumors

Targeting NR2E3 is a potential approach to avoid photoreceptor degeneration in retinitis pigmentosa

Proline links gut microbiome to depression

Novel variant in the DHX38 gene tied to congenital dyserythropoietic anemia with ring sideroblasts

Studies identify genetic risk factors for hyperemesis gravidarum and recurrence

AGEN-1571 reverses ILT-2-mediated immunosuppression to activate antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...